<DOC>
	<DOCNO>NCT01375075</DOCNO>
	<brief_summary>The purpose study determine 12 week treatment LY2484595 administer monotherapy significantly increase high-density lipoprotein cholesterol ( HDL-C ) decrease low-density lipoprotein cholesterol ( LDL-C ) Japanese participant .</brief_summary>
	<brief_title>A Study LY2484595 Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Have Low HDLC High LDLC criterion follow : Low HDL lipid criterion : HDLC &lt; 45 mg/dL ( men ) &lt; 50 mg/dL ( woman ) , LDLC accord Japan Atherosclerosis Society ( JAS ) guideline follow : LDLC &lt; 190 mg/dL ( 01 risk factor ) LDLC &lt; 160 mg/dL ( 2 risk factor ) LDLC &lt; 130 mg/dL ( 3+ risk factor ) , Fasting TG &lt; 400 mg/dL High LDLC lipid criterion : HDLC &lt; 100 mg/dL , LDLC accord JAS guideline follow : LDLC 100190 mg/dL ( 01 risk factor ) LDLC 100160 mg/dL ( 2 risk factor ) LDLC 100130 mg/dL ( 3+ risk factor ) , Fasting TG &lt; 400 mg/dL Note : Subjects diabetes regard 3+ risk factor Male subject : Agree use reliable method birth control study ( 2 week follow last dose study drug ) Female subject : 1 ) Women childbearing potential due surgical sterilization ( least 6 week post surgical bilateral oophorectomy without hysterectomy tubal ligation ) confirm medical history , menopause . Menopausal woman include woman either ) spontaneous amenorrhea least 12 month , induce medical condition anorexia nervosa take medication amenorrhea induce amenorrhea ( example , oral contraceptive , hormone , gonadotropin release hormone , antiestrogens , selective estrogen receptor modulators [ SERMs ] , chemotherapy ) b ) spontaneous amenorrhea 6 12 month folliclestimulating hormone ( FSH ) level great 40 mIU/mL . , 2 ) Women child bear potential test negative pregnancy time enrollment base urine serum pregnancy test agree use reliable method birth control study 2 week follow last dose study drug Have give inform consent participate study At screen , currently enrol , discontinue within last 30 day , clinical trial involve investigational product unapproved use drug device ( investigational product use study ) , concurrently enrol type medical research judge scientifically medically compatible study Have participate within 90 day prior screen clinical trial cholesteryl ester transfer protein ( CETP ) inhibitor ( e.g. , anacetrapib dalcetrapib ) Have complete withdrawn study complete withdrawn study investigate LY2484595 Are unable , unreliable , and/or unwilling provide inform consent , make available duration study , abide procedure study restriction Have recent history clinically significant rash , history clinically severe drugrelated rash , history chronic skin disorder ( psoriasis , eczema urticaria ) , history significant skin hypersensitivity household cosmetic product , allergen per investigator , presence widespread tattoo skin condition limit assessment rash . Subjects develop rash Diet Leadin/Washout Phase randomize Have clinical manifestation coronary heart disease ( CHD ) , stable unstable angina , acute coronary syndrome , myocardial infarction , coronary revascularization procedure include stent placement , symptomatic carotid artery disease symptomatic peripheral arterial disease . Subjects diagnosis abdominal aortic aneurysm exclude study Have systolic blood pressure ( SBP ) &gt; 140 mmHg diastolic blood pressure ( DBP ) &gt; 90 mmHg determine mean 3 standardized measurement sit position randomization Have document hyperaldosteronism Have symptom consistent moderate severe heart failure receive treatment symptomatic congestive heart failure ( CHF ) know leave ventricular ejection fraction ( LVEF ) &lt; 35 % . The absence LVEF measurement prohibit entry study Have one follow abnormality : QTc prolongation ( Bazett 's correct QTc interval [ QTcB ] ) &gt; 450 msec male subject &gt; 470 msec female subject , abnormally wide QRS complex ( result bundle branch block , intraventricular conduction delay , pacemaker ) atrial fibrillation screen electrocardiogram ( ECG ) , previous history QTc prolongation another medication require discontinuation , congenital long QT syndrome , previous history ventricular tachycardia unexplained syncope Have family history long QT syndrome sudden death likely secondary ventricular arrhythmia Have active hepatobiliary disease , serologic evidence past active hepatitis B C , past active gallbladder disease . Subjects diagnose Gilbert syndrome cholecystectomy great 90 day prior screen include Have aspartate aminotransferase ( AST/SGOT ) , alanine aminotransferase ( ALT/SGPT ) , alkaline phosphatase ( ALP ) , total bilirubin &gt; 1.5 time upper limit normal ( ULN ) Have history presence chronic muscular neuromuscular disease include prior rhabdomyolysis druginduced myopathy unexplained/documented elevation creatine kinase ( CK ) ≥3 time ULN Have history discontinuation statin , change statin , dose reduction statin due history hypersensitivity , intolerance adverse effect . Have history increase hepatic enzymes associate use hydroxymethylglutarylcoenzyme A ( HMGCoA ) reductase inhibitor ( statin ) Have history hypersensitivity intolerance drug preparation contain cholesteryl ester transfer protein ( CETP ) inhibitor , include limited torcetrapib , anacetrapib , dalcetrapib Have hemoglobin A1c ≥8.0 % ; use , plan use , likely require insulin course study . Diabetic subject antidiabetic agent lipid modifying effect must stable dose least 30 day prior screen Have serum creatinine ≥2 mg/dL , nephrotic syndrome , end stage renal disease use renal replacement therapy hemodialysis peritoneal dialysis Have hemoglobin &lt; 10 g/dL woman &lt; 11 g/dL men Have current uncontrolled active inflammatory condition infection opinion investigator would influence subject 's ability complete study Have thyroidstimulating hormone ( TSH ) level outside normal reference range . Subjects clinically euthyroid , stable thyroid replacement therapy 60 day prior screen , anticipate remain dose throughout trial period acceptable exception criterion Are woman lactate Have plan likely require major surgery require anesthesia hospitalization course study Have chronic alcohol drug abuse dependency Are currently suspicion cancer history cancer past 2 year , exception excise superficial lesion basal cell carcinoma squamous cell carcinoma skin Have history human immunodeficiency virus ( HIV ) infection Have condition abnormal laboratory value , opinion investigator precludes subject provide informed consent Plan use , likely require , unwilling unable stop adequate washout prescription overthecounter ( OTC ) medication health food intent treat serum lipid ( LDLC , HDLC , triglyceride ) include limited class drug : statin , ezetimibe , bile acid sequestrant , eicosapentaenoic acid ( EPA ) . Subjects take probucol , fibrate nicotinic agent within 8 week screen exclude study Are currently use , plan use , likely require course study systemic corticosteroid ; anabolic agent stable dos estrogen , estrogen/progestin , testosterone replacement therapy Are currently use , plan use , likely require course study , occasional use ( i.e. , every week ) stimulant laxative ( e.g. , bisacodyl ) , osmotic laxative ( e.g. , milk magnesia ) , castor oil Use immunosuppressive therapy within 60 day prior screen likely require immunosuppressive therapy course study Have receive treatment within 30 day prior time study entry drug drug receive regulatory approval indication Have plan adopt diet aggressive carbohydrate restriction weight loss . Currently use , use within 60 day prior screen , plan use trial period prescription OTC formulation intend weight loss Are currently use , use within 60 day prior screen , plan use , likely require course study , drug food inducer ( include rifampin carbamazepine ) moderate strong inhibitor cytochrome P450 3A ( include , ketoconazole , erythromycin grapefruit juice ) ; strong inhibitor organic anion transporter polypeptide 1B1 ( OATP1B1 ) transporter ( include cyclosporine rifampin ) . The drug use topical preparation acceptable</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>